Warp Sciences, founded by former OpenAI CPO Kevin Weil to speed up drug development using AI, emerges from stealth with $215M at an $865M post-money valuation
Context & Ripple Effects
Warp Sciences turns Kevin Weil’s previously reported fundraising plan into a financed, public company. Weil had left OpenAI in April, making the venture a notable migration of frontier-AI product leadership into scientific R&D.
The company enters an AI drug-development field already drawing large checks: Lila Sciences raised $235 million in 2025, while DeepMind spinout Isomorphic Labs had secured drug-discovery partnerships with Eli Lilly and Novartis. Weil has framed Warp’s approach around robotic labs producing data for scientific AI models.
First-order effects
- Warp Sciences has $215 million to build its AI-and-robotics drug-development operation, with an $865 million post-money valuation setting its initial capital-market benchmark.
- Kevin Weil’s move shifts his operating focus from OpenAI’s product organization to Warp Sciences’ effort to commercialize AI for medicines.
Second-order effects
- Lila Sciences and other AI-for-science startups face a better-funded rival for specialized AI, lab-automation talent, and investor attention.
- The Isomorphic Labs partnerships illustrate the commercial bar Warp must meet: drugmakers are likely to assess AI platforms by whether they can connect model output to drug-development workflows.
Third-order effects
- If companies such as Warp, Lila and Isomorphic can pair scientific models with proprietary experimental data, AI drug development may consolidate around capital-intensive platforms rather than standalone software tools.
- Large early financings are making founder pedigree and access to laboratory infrastructure increasingly important gates for entrants in AI-for-science markets.
The trend: AI drug development is becoming a capital-intensive race to combine frontier models, automated experimentation and pharmaceutical distribution.